For example, a trial of selicrelumab, a human IgG2 agonistic mAb against CD40, in 15 patients with melanoma, demonstrated a partial response in 4 patients, some of which were long-lasting responses.97 More recently, selicrelumab in combination with CTLA-4 inhibition showed an overall response rate of 27.3% compared with 10.7% in the anti-CTLA-4 only arm.98–100 There are currently no ongoing trials further exploring selicrelumab in melanoma. This evidence concerns the gene CTLA4 and melanoma.